Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific

Agenda

Agenda

Control of BG by Insulin and Glucagon at the Individual Level

Increased HGP and Reduced Postprandial Glucagon Suppression in T2DM

Agenda

Basal Insulin Treatment Is Essential to Decreasing the FBG Level Continuously and Thoroughly

Basal Insulin Treatment Is Essential to Decreasing the FBG Level Continuously and Thoroughly (cont)

FBG Improvement Results in Better PPG Control

FBG Improvement Results in Better PPG Control (cont)

Basal Insulin Treatment in T2DM

Agenda

ADA/EASD Position Statement: A Patient-Centered Approach

Intensification Options for Patients With T2DM Uncontrolled on Basal Insulin

Premix vs Novel Co-formulated Short- Plus Long-Acting Insulin Analogue Combination

Simplification of Insulin Intensification

Adding a Short-Acting Insulin at Mealtime

IDegAsp Once Daily vs IGlar Once Daily in Patients With T2DM

Complementary Effects of Basal Insulin and GLP-1 RA Therapy

BIAsp 30 Premix vs IDegAsp Twice Daily

Quantity of Insulin: BIAsp 30 Premix vs IDegAsp

Patient-Centered Insulin Intensification

1) 73-Year-Old Woman With T2DM: Insulin Antibody Positive

90-Year-Old Man With T2DM

Simplified Therapy With Coformulated IDegAsp: 78-Year-Old Man With T2DM

IDeg During Hemodialysis

Hemodialysis/CAPD Patient Cases

Hemodialysis Case: Switch From Regular Insulin to IDegAsp

Patient and Physician Perspectives

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)